Skip to main content
Explore URMC
menu

ADORED-Allergic Disease Onset Prevention Study

Research Question:
The primary objective of Parts A1 and A2 of this study is to assess the safety and tolerability of STMC-103H in children and infant subjects at risk for development of allergic disease.

Basic Study Information

Purpose:
Early administration of beneficial bacteria that promote immune tolerance represents a novel approach for the prevention and treatment of allergic diseases, such as atopic dermatitis and asthma. STMC-103H is a live biotherapeutic product (LBP) containing a consortium of intestinal bacteria that may impact the incidence of allergic sensitization and disease in neonates and infants at risk for developing allergy and asthma. STMC-103H is an oral capsule containing powder which will be mixed with a small amount of breastmilk, the participant’s formula, or a milk product. Siolta Therapeutics is testing this investigational drug for the prevention of allergic diseases, including atopic dermatitis (eczema), food allergy, asthma, and allergic rhinitis (hay fever).

Location: UR Medicine
Study Web URL:  https://www.urmc.rochester.edu/childrens-hospital/allergy.aspx
Study Reference #: STUDY00006587

Lead Researcher (Principal Investigator)

Lead Researcher:  Kirsi Jarvinen-seppo

Study Contact Information

Study Coordinator: Allison Leadley
Phone: (585) 275-4640
Email: allergy_research@urmc.rochester.edu

Additional Study Details

Study Details:
Early administration of beneficial bacteria that promote immune tolerance represents a novel approach for the prevention and treatment of allergic diseases, such as atopic dermatitis and asthma. STMC-103H is a live biotherapeutic product (LBP) containing a consortium of intestinal bacteria that may impact the incidence of allergic sensitization and disease in neonates and infants at risk for developing allergy and asthma. STMC-103H is an oral capsule containing powder which will be mixed with a small amount of breastmilk, the participant’s formula, or a milk product. Siolta Therapeutics is testing this investigational drug for the prevention of allergic diseases, including atopic dermatitis (eczema), food allergy, asthma, and allergic rhinitis (hay fever).

Number of Visits:  6 to 10
Parking:  Reimbursed
Reimbursement:  Yes

Learn More About These Conditions

More information about Allergic rhinitis

More information about Dermatitis, Atopic

More information about Rhinitis, Allergic, Perennial

More information about Rhinitis, Allergic, Seasonal

Want to participate in this study?

This field is required
This field is required
You must agree to be contacted to continue.


Return to Search